Anti CD38 chimeric antigen receptor T-cell therapy - Celularity/Sorrento Therapeutics

Drug Profile

Anti CD38 chimeric antigen receptor T-cell therapy - Celularity/Sorrento Therapeutics

Latest Information Update: 20 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sorrento Therapeutics
  • Developer Celularity; Sorrento Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 19 Apr 2018 Sorrento Therapeutics has patents pending for the CAR T-Cell based technology
  • 05 Apr 2018 Phase-I clinical trials in Multiple myeloma (Refractory metastatic disease, Recurrent) in USA (IV)
  • 08 Mar 2018 Sorrento Pharma submits IND application for anti-CD38 CAR-T cell therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top